EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effects of Dorzagliatin, a Glucokinase Activator, on α- and β-Cell Function in Individuals With Impaired and Normal Glucose Tolerance

Zhengli Bai, Ke Wang, Tiffany Yau, Cadmon K P Lim, Sandra T F Tsoi iD, Baoqi Fan iD, Claudia H T Tam iD, Emily W M Poon, Andrea O Y Luk iD, Alice P S Kong iD, Ronald C W Ma iD, Ele Ferrannini iD und 4 weitere

Diabetes · 2025

DOI: 10.2337/db24-1130 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, 2025. Verfasst von Zhengli Bai und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Glucokinase, Glucose Intolerance, Glucagon-Secreting Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Hua Medicine Investigator Initiated Study, Health and Medical Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dorzagliatin is a dual-acting allosteric activator of glucokinase (GCK). Dorzagliatin improved second-phase insulin secretion in individuals with type 2 diabetes and heterozygous carriers of GCK mutations. We investigated the effects of dorzagliatin on pancreatic insulin, glucagon, and glucagon-like-peptide 1 (GLP-1) secretion in individuals with impaired glucose tolerance (IGT) and normal glucose tolerance (NGT). In a double-blind, randomized, crossover, single-dose study, 9 participants with IGT and 10 with NGT underwent 2-h 12 mmol/L hyperglycemic clamp following a single dose of dorzagliatin 50 mg or matched placebo. Plasma insulin, C-peptide, glucagon, and total GLP-1 levels were measured at regular intervals. There were no differences in first-phase insulin after the dorzagliatin dose in either group. Dorzagliatin significantly increased second-phase insulin secretion rate and β-cell glucose sensitivity by 1.3-fold compared with placebo in IGT but remained similar in NGT. Dorzagliatin increased basal plasma insulin in the NGT group only. Glucagon (area under the curve0–120 min = 161 ± 58 vs. 234 ± 70 pmol*min/L [mean ± SD]; P = 0.01) was suppressed after dorzagliatin in the NGT group but not the IGT group. Plasma glucagon was positively correlated with total GLP-1 levels. Dorzagliatin did not affect insulin sensitivity in either group. Dorzagliatin has different actions on β- and α-cells depending on glucose tolerance, increasing second-phase insulin secretion in IGT while enhancing glucose-suppression of glucagon secretion in NGT. Article Highlights Dorzagliatin is a dual-acting allosteric glucokinase (GCK) activator that increases β-cell glucose sensitivity and second-phase insulin in GCK monogenic diabetes of the young. Actions of dorzagliatin on α- and β-cell function in normal and impaired glucose tolerance are unknown. In this study, dorzagliatin increased second-phase insulin in individuals with impaired glucose tolerance while suppressing glucagon in participants with normal glucose tolerance during a hyperglycemic clamp. With increasing glucose, plasma glucagon and total GLP-1 levels declined progressively. A modest to moderate positive correlation between glucagon and total GLP-1 was observed under both dorzagliatin and placebo treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Secreting CellsGlucokinaseGlucose IntoleranceGlucagon-Secreting CellsHumansMaleFemaleGlucagonMiddle AgedDouble-Blind MethodGlucagon-Like Peptide 1Cross-Over StudiesAdultInsulinC-PeptideBlood GlucoseGlucose Clamp TechniqueDiabetes Mellitus, Type 2Insulin SecretionGlucose Tolerance Test

Substanzen

GlucokinaseGlucagonGlucagon-Like Peptide 1InsulinC-PeptideBlood Glucose

Autor:innen und Institutionen

  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
  • Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
  • Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
  • Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • CNR Institute of Clinical Physiology, Pisa, Italy.
  • CNR Institute of Neuroscience, Padua, Italy.

ORCID-Profile: Sandra T F Tsoi, Baoqi Fan, Claudia H T Tam, Andrea O Y Luk, Alice P S Kong, Ronald C W Ma, Ele Ferrannini, Andrea Mari, Li Chen, Juliana C N Chan, Elaine Chow

Förderung

  • Hua Medicine Investigator Initiated Study
  • Health and Medical Research Fund

Zitieren

APA

Bai, Z., Wang, K., Yau, T., Lim, C. K. P., Tsoi, S. T. F., Fan, B., Tam, C. H. T., Poon, E. W. M., Luk, A. O. Y., Kong, A. P. S., Ma, R. C. W., Ferrannini, E., Mari, A., Chen, L., Chan, J. C. N., & Chow, E. (2025). Effects of Dorzagliatin, a Glucokinase Activator, on α- and β-Cell Function in Individuals With Impaired and Normal Glucose Tolerance. Diabetes. https://doi.org/10.2337/db24-1130

Vancouver

Bai Z, Wang K, Yau T, Lim CKP, Tsoi STF, Fan B, et al. Effects of Dorzagliatin, a Glucokinase Activator, on α- and β-Cell Function in Individuals With Impaired and Normal Glucose Tolerance. Diabetes. 2025. doi:10.2337/db24-1130

BibTeX
@article{Bai2025,
  author = {Bai, Zhengli and Wang, Ke and Yau, Tiffany and Lim, Cadmon K P and Tsoi, Sandra T F and Fan, Baoqi and Tam, Claudia H T and Poon, Emily W M and Luk, Andrea O Y and Kong, Alice P S and Ma, Ronald C W and Ferrannini, Ele and Mari, Andrea and Chen, Li and Chan, Juliana C N and Chow, Elaine},
  title = {Effects of Dorzagliatin, a Glucokinase Activator, on α- and β-Cell Function in Individuals With Impaired and Normal Glucose Tolerance},
  journal = {Diabetes},
  year = {2025},
  doi = {10.2337/db24-1130}
}
Kostenlos starten →